SNAPSHOT
GeNeuro is developing drugs for targeting a novel disease mechanism that is directly causal, not one indirectly related to the disease symptoms targeted by conventional drugs: human endogenous retrovirus (HERV) expression. GeNeuro’s lead program, for the drug coded GNbAC1, is in a Phase 2b trial for treating relapsing remitting MS, conducted in partnership with Servier, with sixmonth data expected in October this year. GNbAC1 is also in Phase 2 trials for Type 1 diabetes, with results expected in the second half of 2018.